
    
      A Phase 1, randomized,double-blind, placebo-controlled clinical study of Nexvax2, in adult
      subjects with confirmed CeD who, have been following a gluten free diet for at least 12
      consecutive months prior to screening. The study will evaluate the safety and tolerability of
      Nexvax2 administered subcutaneously and will compare the bioavailability of subcutaneous
      versus intradermal administration. The study plan consists of 3 periods: a screening period
      of 3 to 5 weeks, a 46-day treatment period, and a 30-day post-treatment observational
      follow-up visit.
    
  